 | • レポートコード：MRC2304L050 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、227ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に1,391.34百万ドルであった世界の膀胱がん治療薬市場規模が、2022年に1,601.30百万ドルへと拡大し、その後CAGR 15.34％で成長して2027年までに3,276.63百万ドルに達すると予測しています。当書は、膀胱がん治療薬の世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別（筋層浸潤性膀胱がん、非筋層浸潤性膀胱がん）分析、悪性度別（高悪性度腫瘍、低悪性度腫瘍）分析、流通別（病院薬局、オンライン薬局、小売薬局）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目をまとめています。なお、当書に掲載されている企業情報には、Agilent Technologies, Inc.、AstraZeneca PLC、Bayer AG、Bristol-Myers Squibb Co、Eisai Co. Ltd、Eli Lilly and Co.、F. Hoffmann-La Roche AG、Genentech, Inc.、HAMLET Pharma AB、Johnson & Johnson、Medtronic PLCなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の膀胱がん治療薬市場規模：種類別 - 筋層浸潤性膀胱がんにおける市場規模 - 非筋層浸潤性膀胱がんにおける市場規模 ・世界の膀胱がん治療薬市場規模：悪性度別 - 高悪性度腫瘍における市場規模 - 低悪性度腫瘍における市場規模 ・世界の膀胱がん治療薬市場規模：流通別 - 病院薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 ・世界の膀胱がん治療薬市場規模：地域別 - 南北アメリカの膀胱がん治療薬市場規模 アメリカの膀胱がん治療薬市場規模 カナダの膀胱がん治療薬市場規模 ブラジルの膀胱がん治療薬市場規模 ... - アジア太平洋の膀胱がん治療薬市場規模 日本の膀胱がん治療薬市場規模 中国の膀胱がん治療薬市場規模 インドの膀胱がん治療薬市場規模 韓国の膀胱がん治療薬市場規模 台湾の膀胱がん治療薬市場規模 ... - ヨーロッパ/中東/アフリカの膀胱がん治療薬市場規模 イギリスの膀胱がん治療薬市場規模 ドイツの膀胱がん治療薬市場規模 フランスの膀胱がん治療薬市場規模 ロシアの膀胱がん治療薬市場規模 ... - その他地域の膀胱がん治療薬市場規模 ・競争状況 ・企業情報 |
The Global Bladder Cancer Drugs Market size was estimated at USD 1,391.34 million in 2021 and expected to reach USD 1,601.30 million in 2022, and is projected to grow at a CAGR 15.34% to reach USD 3,276.63 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Bladder Cancer Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Muscle-Invasive Bladder Cancer and Non-Muscle-Invasive Bladder cancer.
Based on Malignant Potential, the market was studied across High-Grade Tumors and Low-Grade Tumors.
Based on Distribution, the market was studied across Hospitals Pharmacies, Online Pharmacies, and Retail Pharmacies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Bladder Cancer Drugs market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Bladder Cancer Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Bladder Cancer Drugs Market, including Agilent Technologies, Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co, Eisai Co. Ltd, Eli Lilly and Co., F. Hoffmann-La Roche AG, Genentech, Inc., HAMLET Pharma AB, Johnson & Johnson, Medtronic PLC, Merck KGaA, Novartis AG, Pfizer Inc., PHOTOCURE ASA, Sanofi SA, SBI Pharmaceuticals Co., Ltd., Sesen Bio, Inc., Sitka Biopharma Inc., and UroGen Pharma, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Bladder Cancer Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Bladder Cancer Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Bladder Cancer Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Bladder Cancer Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Bladder Cancer Drugs Market?
6. What is the market share of the leading vendors in the Global Bladder Cancer Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Bladder Cancer Drugs Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Number of bladder cancer incidence has been on the rise
5.1.1.2. Unhygienic workplace exposures and increase in smoking habits
5.1.1.3. Recent development and drug approvals for bladder cancer
5.1.2. Restraints
5.1.2.1. Growing use of biologics and targeted therapies
5.1.3. Opportunities
5.1.3.1. Utilization of nanotechnology for drugs production
5.1.3.2. Strategic collaboration for market penetration
5.1.4. Challenges
5.1.4.1. Side effects related to bladder cancer drugs
5.2. Cumulative Impact of COVID-19
6. Bladder Cancer Drugs Market, by Type
6.1. Introduction
6.2. Muscle-Invasive Bladder Cancer
6.3. Non-Muscle-Invasive Bladder cancer
7. Bladder Cancer Drugs Market, by Malignant Potential
7.1. Introduction
7.2. High-Grade Tumors
7.3. Low-Grade Tumors
8. Bladder Cancer Drugs Market, by Distribution
8.1. Introduction
8.2. Hospitals Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Americas Bladder Cancer Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Bladder Cancer Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Bladder Cancer Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Agilent Technologies, Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. AstraZeneca PLC
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Bayer AG
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Bristol-Myers Squibb Co
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Eisai Co. Ltd
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Eli Lilly and Co.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. F. Hoffmann-La Roche AG
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Genentech, Inc.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. HAMLET Pharma AB
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Johnson & Johnson
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Medtronic PLC
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Merck KGaA
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Novartis AG
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Pfizer Inc.
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. PHOTOCURE ASA
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Sanofi SA
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. SBI Pharmaceuticals Co., Ltd.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Sesen Bio, Inc.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Sitka Biopharma Inc.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. UroGen Pharma, Inc.
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
